Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease

Biomolecules. 2023 Oct 23;13(10):1562. doi: 10.3390/biom13101562.

Abstract

Krabbe disease is a rare neurodegenerative disease with an autosomal recessive character caused by a mutation in the GALC gene. The mutation leads to an accumulation of psychosine and a subsequent degeneration of oligodendrocytes and Schwann cells. Psychosine is the main biomarker of the disease. The Twitcher mouse is the most commonly used animal model to study Krabbe disease. Although there are many references to this model in the literature, the lipidomic study of nervous system tissues in the Twitcher model has received little attention. This study focuses on the comparison of the lipid profiles of four nervous system tissues (brain, cerebellum, spinal cord, and sciatic nerve) in the Twitcher mouse compared to the wild-type mouse. Altogether, approximately 230 molecular species belonging to 19 lipid classes were annotated and quantified. A comparison at the levels of class, molecular species, and lipid building blocks showed significant differences between the two groups, particularly in the sciatic nerve. The in-depth study of the lipid phenotype made it possible to hypothesize the genes and enzymes involved in the changes. The integration of metabolic data with genetic data may be useful from a systems biology perspective to gain a better understanding of the molecular basis of the disease.

Keywords: Krabbe disease; LC/MS; Twitcher mouse; lipidomics; psychosine; untargeted mass spectrometry.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain / metabolism
  • Disease Models, Animal
  • Leukodystrophy, Globoid Cell* / genetics
  • Leukodystrophy, Globoid Cell* / metabolism
  • Lipidomics
  • Mice
  • Neurodegenerative Diseases* / metabolism
  • Psychosine / metabolism

Substances

  • Psychosine

Grants and funding

This research was supported by the European Leukodystrophy Association (ELA) International, under the framework of the projects “Pre-clinical testing of single and combined autophagy modulation by Lithium and Rapamycin in Globoid Cell Leukodystrophy” (grant agreement no. 2018-008F2), “nanoERT—Nanoparticle based Enzyme Replacement Therapy for the treatment of Krabbe disease: a pre-clinical study in the Twitcher Mouse” (grant agreement no. G.A. ELA n. 2019-008I2AV1—NanoERT) and the European Union—NextGenerationEU under the Italian Ministry of University and Research (MUR) National Innovation Ecosystem grant ECS00000041—VITALITY.